Sandimmune® to Neoral® conversion and value of abbreviated AUC monitoring in stable pediatric kidney transplant recipients

Pediatric Transplantation

Volumn 3, Issue 4, 1999, Pages 282-287

  Kelles, Annemarie ^b   Herman, Jean ^b   Tjandra Maga, T Budya ^b   Van Damme Lombaerts, Rita ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b NONE

Author keywords

Abbreviated AUC monitoring; Neoral; Pediatric renal transplantation; Pharmacokinetics; Sandimmune

Indexed keywords

CYCLOSPORIN A; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CHILD; CLINICAL ARTICLE; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG MONITORING; FEMALE; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HUMAN; KIDNEY TRANSPLANTATION; MALE; ORAL DRUG ADMINISTRATION; PEDIATRIC SURGERY; PREDICTION; BIOAVAILABILITY; BLOOD; COMPARATIVE STUDY; EMULSION; FOLLOW UP; GRAFT REJECTION; METHODOLOGY; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADOLESCENT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHILD; CYCLOSPORINE; DRUG MONITORING; EMULSIONS; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; TREATMENT OUTCOME;

EID: 0032589698     PISSN: 13973142     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3046.1999.00058.x     Document Type: Article

References (22)

1. ENGLUND M, BERG U, BOHLIN A, TIBELL A, TYDEN G. Ten years' experience of renal transplantation in children in the cyclosporine era. Transplantation 1993: 56: 1124-1130.
2. LINDHOLM A, KAHAN BD. Influence of cyclosporine pharnacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther 1993: 54: 205-218.
3. KELLES A, VAN DAMME-LOMBAERTS R, TJANDRA-MAGA TB, VAN DAMME B. Long-term cyclosporin A pharmacokinetic profiles in pediatric renal transplant recipients. Transpl Int 1996: 9: 546-550.
4. BÖKENKAMP A, OFFNER G, HOYER P, VESTER U, WONIGEIT K, BRODEHL J. Improved absorption of cyclosporin A from a new microemulsion formulation: implications for dosage and monitoring. Pediatr Nephrol 1995: 9: 196-198.
5. KAHAN BD, DUNN J, FITTS C, et al. Reduced inter- and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low fat meals, or high-fat meals. Transplantation 1995: 59: 505-511.
6. HOLT D, MUELLER E, KOVARIK J, VAN BREE J, KUTZ K. The pharmacokinetics of Sandimmun Neoral: a new oral formulation of cyclosporine. Transplant Proc 1994: 26: 2935-2939.
7. KAHAN BD, DUNN J, VAN BUREN D, et al. The trough levels and exposure in stable renal transplant recipients. Transplant Proc 1994: 26: 2940-2943.
8. FRIMAN S, BACKMAN L. A new microemulsion formulation of cyclosporin. Clin Pharmacokinet 1996: 30: 181-193.
9. KABASAKUL S, CLARKE M, KANE H, KARSTEN J, CLARK G. Comparison of Neoral and Sandimmune cyclosporin A pharmacokinetic profiles in young renal transplant recipients. Pediatr Nephrol 1997: 11: 318-321.
10. KRMAR RW, WÔHL E, DING R, AULMANN M, SCHÖRER K. Pharmacokinetics of a new microemulsion formulation of cyclosporin A (Neoral) in young patients after renal transplantation. Transpl Int 1996: 9: 476-480.
11. HOYER PF. Cyclosporin A (Neoral) in pediatric organ transplantation. Pediatr Transplantation 1998: 2: 35-39.
12. ANDRÉ J, DESCAMPS J, GUEGUEN R, JACQUES J. Tension artérielle chez l'enfant et l'adolescent. Influence de modalités de mesure. Distribution de valeurs fréquentes et référence à l'âge et à la taille. Arch Mal Coeur 1981: 74: 3-13.
13. ETTENGER R, SMITH H, KAISER B, et al. Use of Neoral in pediatric renal transplantation. Transplant Proc 1996: 28: 2257-2258.
14. HOYER P, BÖKENKAMP A, VESTER U, OFFNER G, BRODEHL J. Conversion from Sandimmune to Neoral and induction therapy with Neoral in pediatric renal transplant recipients. Transplant Proc 1996: 28: 2259-2261.
15. KOVARIK J, KALLAY Z, MUELLER E, VAN BREE J, ARNS W, RENNER E. Acute effect of cyclosporin on renal function following the initial changeover to a microemulsion formulation in stable kidney transplant patients. Transpl Int 1995: 8: 335-339.
16. WILCZEK H, BERGLIN E, BLOHME I, et al. The Swedisch nationwide experience of converting transplant patients treated with Sandimmun to the new galenic formulation sandimmun-Neoral. Transpl Proc 1996: 29: 280-283.
17. LIN C, LEE S. Comparison of pharmacokinetics between CyA capsules and Sandimmun Neoral in pediatric patients. Transplant Proc 1994: 26: 2973-2974.
18. COLE E, KEOWN P, LANDBERG D, et al. Safety and tolerability of cyclosporine and cyclosporine microemulsion during 18 months of follow-up in stable renal transplant recipients: a report of the Canadian Neoral Renal Study Group. Transplantation 1998: 65: 505-510.
19. GREVEL J, WELSH MS, KAHAN BD. Cyclosporine monitoring in renal transplantation: area under the curve monitoring is superior to trough-level monitoring. Ther Drug Monit 1989: 11: 246-248.
20. CANTAROVICH M, BESNER JG, BARKUN JS, ELSTEIN E, LOERTSCHER R. Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy. Clin Transplant 1998: 12: 243-249.
21. KOVARIK J, MUELLER E, VAN BREE J, et al. Cyclosporine pharmacokinetics and variability from a microemulsion formation-a multicenter investigation in kidney transplant recipients. Transplantation 1994: 58: 658-663.
22. AMANTE A, KAHAN BD. Abbreviated AUC strategy for montitoring cyclosporine microemulsion therapy in the immediate poststransplant period. Transplant Proc 1996: 28: 2162-2163.